Eli Lilly and Company
Anti-RANKL antibodies and uses thereof

Last updated:

Abstract:

Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.

Status:
Grant
Type:

Utility

Filling date:

20 Oct 2017

Issue date:

9 Feb 2021